Phase II Study of Apatinib as Third- or Further-line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 16 Jul 2022 Status changed from recruiting to completed.
- 16 Sep 2019 Results (n=40, data cut-off date- 15 Nov 2018 ) published in the British Journal of Cancer.
- 26 Sep 2018 Results (Data cut off March 2018; n=40) assessing Apatinib in patients with ES-SCLC presented at the 19th World Conference on Lung Cancer